BCL-2 family proteins

Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy

John C. Reed, Toshiyuki Miyashita, Shinichi Takayama, Hong-Gang Wang, Takaaki Sato, Stanislaw Krajewski, Christine Aimésempé, Sharon Bodrug, Shinichi Kitada, Motoi Hanada

Research output: Contribution to journalArticle

420 Citations (Scopus)

Abstract

The BCL-2 gene was first discovered because of its involvement in the t(14;18) chromosomal translocations commonly found in lymphomas, which result in deregulation of BCL-2 gene expression and cause inappropriately high levels of Bcl-2 protein production. Expression of the BCL-2 gene can also become altered in human cancers through other mechanisms, including loss of the p53 tumor suppressor which normally functions as a repressor of BCL-2 gene expression in some tissues. Bcl-2 is a blocker of programmed cell death and apoptosis that contributes to neoplastic cell expansion by preventing cell turnover caused by physiological cell death mechanisms, as opposed to accelerating rates of cell division. Overproduction of the Bcl-2 protein also prevents cell death induced by nearly all cytotoxic anticancer drugs and radiation, thus contributing to treatment failures in patients with some types of cancer. Several homologs of Bcl-2 have recently been discovered, some of which function as inhibitors of cell death and others as promoters of apoptosis that oppose the actions of the Bcl-2 protein. Many of these Bcl-2 family proteins can interact through formation of homo- and heterotypic dimers. In addition, several nonhomologous proteins have been identified that bind to Bcl-2 and that can modulate apoptosis. These protein-protein interactions may eventual serve as targets for pharmacologically manipulating the physiological cell death pathway for treatment of cancer and several other diseases.

Original languageEnglish (US)
Pages (from-to)23-32
Number of pages10
JournalJournal of cellular biochemistry
Volume60
Issue number1
DOIs
StatePublished - Feb 16 1996

Fingerprint

Cell death
Cell Death
Neoplasms
Proteins
Apoptosis
Gene expression
Therapeutics
Genes
Gene Expression
Genetic Translocation
Deregulation
Treatment Failure
Cell Division
Dimers
Tumors
Lymphoma
Cells
Radiation
Tissue
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Reed, John C. ; Miyashita, Toshiyuki ; Takayama, Shinichi ; Wang, Hong-Gang ; Sato, Takaaki ; Krajewski, Stanislaw ; Aimésempé, Christine ; Bodrug, Sharon ; Kitada, Shinichi ; Hanada, Motoi. / BCL-2 family proteins : Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. In: Journal of cellular biochemistry. 1996 ; Vol. 60, No. 1. pp. 23-32.
@article{f6a284d9fc074f67b4832879f86212cd,
title = "BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy",
abstract = "The BCL-2 gene was first discovered because of its involvement in the t(14;18) chromosomal translocations commonly found in lymphomas, which result in deregulation of BCL-2 gene expression and cause inappropriately high levels of Bcl-2 protein production. Expression of the BCL-2 gene can also become altered in human cancers through other mechanisms, including loss of the p53 tumor suppressor which normally functions as a repressor of BCL-2 gene expression in some tissues. Bcl-2 is a blocker of programmed cell death and apoptosis that contributes to neoplastic cell expansion by preventing cell turnover caused by physiological cell death mechanisms, as opposed to accelerating rates of cell division. Overproduction of the Bcl-2 protein also prevents cell death induced by nearly all cytotoxic anticancer drugs and radiation, thus contributing to treatment failures in patients with some types of cancer. Several homologs of Bcl-2 have recently been discovered, some of which function as inhibitors of cell death and others as promoters of apoptosis that oppose the actions of the Bcl-2 protein. Many of these Bcl-2 family proteins can interact through formation of homo- and heterotypic dimers. In addition, several nonhomologous proteins have been identified that bind to Bcl-2 and that can modulate apoptosis. These protein-protein interactions may eventual serve as targets for pharmacologically manipulating the physiological cell death pathway for treatment of cancer and several other diseases.",
author = "Reed, {John C.} and Toshiyuki Miyashita and Shinichi Takayama and Hong-Gang Wang and Takaaki Sato and Stanislaw Krajewski and Christine Aim{\'e}semp{\'e} and Sharon Bodrug and Shinichi Kitada and Motoi Hanada",
year = "1996",
month = "2",
day = "16",
doi = "10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5",
language = "English (US)",
volume = "60",
pages = "23--32",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "1",

}

BCL-2 family proteins : Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. / Reed, John C.; Miyashita, Toshiyuki; Takayama, Shinichi; Wang, Hong-Gang; Sato, Takaaki; Krajewski, Stanislaw; Aimésempé, Christine; Bodrug, Sharon; Kitada, Shinichi; Hanada, Motoi.

In: Journal of cellular biochemistry, Vol. 60, No. 1, 16.02.1996, p. 23-32.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BCL-2 family proteins

T2 - Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy

AU - Reed, John C.

AU - Miyashita, Toshiyuki

AU - Takayama, Shinichi

AU - Wang, Hong-Gang

AU - Sato, Takaaki

AU - Krajewski, Stanislaw

AU - Aimésempé, Christine

AU - Bodrug, Sharon

AU - Kitada, Shinichi

AU - Hanada, Motoi

PY - 1996/2/16

Y1 - 1996/2/16

N2 - The BCL-2 gene was first discovered because of its involvement in the t(14;18) chromosomal translocations commonly found in lymphomas, which result in deregulation of BCL-2 gene expression and cause inappropriately high levels of Bcl-2 protein production. Expression of the BCL-2 gene can also become altered in human cancers through other mechanisms, including loss of the p53 tumor suppressor which normally functions as a repressor of BCL-2 gene expression in some tissues. Bcl-2 is a blocker of programmed cell death and apoptosis that contributes to neoplastic cell expansion by preventing cell turnover caused by physiological cell death mechanisms, as opposed to accelerating rates of cell division. Overproduction of the Bcl-2 protein also prevents cell death induced by nearly all cytotoxic anticancer drugs and radiation, thus contributing to treatment failures in patients with some types of cancer. Several homologs of Bcl-2 have recently been discovered, some of which function as inhibitors of cell death and others as promoters of apoptosis that oppose the actions of the Bcl-2 protein. Many of these Bcl-2 family proteins can interact through formation of homo- and heterotypic dimers. In addition, several nonhomologous proteins have been identified that bind to Bcl-2 and that can modulate apoptosis. These protein-protein interactions may eventual serve as targets for pharmacologically manipulating the physiological cell death pathway for treatment of cancer and several other diseases.

AB - The BCL-2 gene was first discovered because of its involvement in the t(14;18) chromosomal translocations commonly found in lymphomas, which result in deregulation of BCL-2 gene expression and cause inappropriately high levels of Bcl-2 protein production. Expression of the BCL-2 gene can also become altered in human cancers through other mechanisms, including loss of the p53 tumor suppressor which normally functions as a repressor of BCL-2 gene expression in some tissues. Bcl-2 is a blocker of programmed cell death and apoptosis that contributes to neoplastic cell expansion by preventing cell turnover caused by physiological cell death mechanisms, as opposed to accelerating rates of cell division. Overproduction of the Bcl-2 protein also prevents cell death induced by nearly all cytotoxic anticancer drugs and radiation, thus contributing to treatment failures in patients with some types of cancer. Several homologs of Bcl-2 have recently been discovered, some of which function as inhibitors of cell death and others as promoters of apoptosis that oppose the actions of the Bcl-2 protein. Many of these Bcl-2 family proteins can interact through formation of homo- and heterotypic dimers. In addition, several nonhomologous proteins have been identified that bind to Bcl-2 and that can modulate apoptosis. These protein-protein interactions may eventual serve as targets for pharmacologically manipulating the physiological cell death pathway for treatment of cancer and several other diseases.

UR - http://www.scopus.com/inward/record.url?scp=9044225527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044225527&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5

DO - 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.0.CO;2-5

M3 - Article

VL - 60

SP - 23

EP - 32

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 1

ER -